Combination of Lurbinectedin plus Irinotecan: Preclinical and Early Clinical Results in Relapsed Small Cell Lung Cancer Patients - PubMed
5 days ago
- #Irinotecan
- #Lurbinectedin
- #SCLC
- Novel treatment approaches are needed for relapsed small cell lung cancer (SCLC).
- Lurbinectedin combined with irinotecan showed synergistic antitumor effects in preclinical models.
- The combination impaired S-phase entry, enhanced DNA damage, and induced apoptosis.
- A phase I/II trial recommended a dose of lurbinectedin 2.0 mg/m² and irinotecan 75 mg/m².
- In 21 relapsed SCLC patients, the combination showed a 61.9% overall response rate.
- Median progression-free survival was 7.2 months, and median overall survival was 12.3 months.
- Common toxicities included myelosuppression, fatigue, gastrointestinal disorders, and decreased appetite.
- Early clinical data indicate promising antitumor activity and a predictable safety profile.
- Further development of this combination for relapsed SCLC is ongoing.